What is Symic Biomedical?
Symic Biomedical operates at the intersection of biopharmaceutical innovation and matrix biology. The company specializes in the development of novel therapeutics inspired by naturally occurring macromolecules that regulate the extracellular matrix. By targeting these fundamental biological pathways, Symic Bio aims to provide transformative treatments for a range of conditions, including osteoarthritis and peripheral vein graft failure. With a diversified research focus spanning fibrosis, oncology, and central nervous system disorders, the company is positioned as a significant player in the next generation of precision medicine. Its clinical candidates, such as SB-061 and SB-030, represent a shift toward disease-modifying interventions rather than mere symptom management.
How much funding has Symic Biomedical raised?
Symic Biomedical has raised a total of $56M across 3 funding rounds:
Series A
$15M
Series B
$30M
Unspecified
$11M
Series A (2015): $15M with participation from Mitsui Global Investment, QB3 Partners, Ally Bridge Group, Den Danske Forskningsfond, Lilly Ventures, Mission Bay Capital, InCube Ventures, and Purdue Foundry Investment Fund
Series B (2017): $30M led by HEDA Ventures and Lily Ventures
Unspecified (2019): $11M supported by Cell Innovation Partners
Key Investors in Symic Biomedical
Mitsui Global Investment
Mitsui & Co. Global Investment, Inc. specializes in guiding innovative entrepreneurs by providing not just financial support but also strategic guidance to help them reach the global stage.
Ally Bridge Group
Ally Bridge Group is a global healthcare investment management firm that specializes in high-impact life science innovation, managing over $6 billion in transactions since its inception in 2013.
Lilly Ventures
Lilly Ventures has its roots in the scientific tradition of Eli Lilly and Company, seeking great companies with compelling life science innovations to provide both financial and intellectual resources.
What's next for Symic Biomedical?
Looking ahead, Symic Biomedical is poised to leverage its recent capital influx to accelerate clinical trial milestones and expand its therapeutic reach. The company's strategic roadmap focuses on validating its matrix-targeting platform across broader disease states, potentially unlocking new value in the oncology and fibrosis markets. As the firm matures, the emphasis will likely shift toward establishing commercial partnerships or licensing agreements that can scale its proprietary technology globally. By maintaining a disciplined approach to R&D and capital allocation, Symic Bio is well-positioned to navigate the complexities of the biopharmaceutical landscape and deliver long-term value to its stakeholders.
See full Symic Biomedical company page
